Kisunla (Donanemab): A Novel Breakthrough Illuminating a Path to Better Alzheimer’s Outcomes

Year : 2025 | Volume : 15 | Issue : 03 | Page : 37 45
    By

    Muchukota Sushma,

  • Alena Reji Thomas,

  • Jayashree S,

  • Priya Singha,

  • Payal Baral,

  • Isbha Stephen,

  • Shobha R. R. Hiremath,

  1. Associate Professor, Department of Pharmacy Practice, Aditya Bangalore Institute of Pharmacy Education & Research (ABIPER), Yelahanka, Bangalore, Karnataka, India
  2. Associate Professor, Department of Pharmacy Practice, Aditya Bangalore Institute of Pharmacy Education & Research (ABIPER), Yelahanka, Bangalore, Karnataka, India
  3. Pharm D. Student, Department of Pharmacy Practice, Aditya Bangalore Institute of Pharmacy Education & Research (ABIPER), Yelahanka, Bangalore, Karnataka, India
  4. Pharm D. Student, Department of Pharmacy Practice, Aditya Bangalore Institute of Pharmacy Education & Research (ABIPER), Yelahanka, Bangalore, Karnataka, India
  5. Pharm D. Student, Department of Pharmacy Practice, Aditya Bangalore Institute of Pharmacy Education & Research (ABIPER), Yelahanka, Bangalore, Karnataka, India
  6. Pharm D. Student, Department of Pharmacy Practice, Aditya Bangalore Institute of Pharmacy Education & Research (ABIPER), Yelahanka, Bangalore, Karnataka, India
  7. Professor and Director, Department of Pharmacy Practice, Aditya Bangalore Institute of Pharmacy Education & Research (ABIPER), Yelahanka, Bangalore, Karnataka, India

Abstract

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative condition marked by cognitive decline, memory loss, and loss of independence. Despite decades of extensive research, disease-modifying treatments have been limited in success. Recent therapeutic advancements have led to the development of monoclonal antibodies targeting amyloid-beta (Aβ) plaques, particularly the pyroglutamate-modified variant, a key pathological hallmark of AD. Objectives: This review aims to explore the therapeutic potential of Donanemab (Kisunla), a novel monoclonal antibody, in slowing disease progression in early symptomatic AD. The study also seeks to assess its clinical efficacy, safety profile, and regulatory journey, while comparing it to other amyloid-targeting therapies. Methodology: A comprehensive analysis of published literature and clinical trial data was conducted, with a focus on the TRAILBLAZER-ALZ clinical programs. Key inclusion and exclusion criteria of the studies were assessed, and trial outcomes related to cognitive performance, amyloid clearance, and safety (especially amyloid-related imaging abnormalities-ARIA) were reviewed. Comparisons were drawn with other similar agents to evaluate relative effectiveness. Results: Donanemab demonstrated significant efficacy in reducing amyloid burden and slowing cognitive decline in early symptomatic patients. The TRAILBLAZER-ALZ trials presented strong clinical evidence for amyloid clearance and improved patient outcomes. However, safety concerns, like ARIA, were reported and carefully monitored. Regulatory agencies acknowledged the potential of Donanemab, granting accelerated approvals based on trial outcomes. Conclusion: Donanemab represents a promising advancement in AD therapeutics, potentially altering the treatment landscape through disease modification. Its early intervention approach and favorable efficacy outcomes indicate a hopeful shift in Alzheimer’s management, though long-term safety and comparative effectiveness require further evaluation.

Keywords: Alzheimer’s disease, amyloid-beta, disease-modifying therapy, Donanemab, Kisunla, monoclonal antibody

[This article belongs to Research and Reviews: A Journal of Neuroscience ]

How to cite this article:
Muchukota Sushma, Alena Reji Thomas, Jayashree S, Priya Singha, Payal Baral, Isbha Stephen, Shobha R. R. Hiremath. Kisunla (Donanemab): A Novel Breakthrough Illuminating a Path to Better Alzheimer’s Outcomes. Research and Reviews: A Journal of Neuroscience. 2025; 15(03):37-45.
How to cite this URL:
Muchukota Sushma, Alena Reji Thomas, Jayashree S, Priya Singha, Payal Baral, Isbha Stephen, Shobha R. R. Hiremath. Kisunla (Donanemab): A Novel Breakthrough Illuminating a Path to Better Alzheimer’s Outcomes. Research and Reviews: A Journal of Neuroscience. 2025; 15(03):37-45. Available from: https://journals.stmjournals.com/rrjons/article=2025/view=233999


References

  1. Rosende-Roca M, García-Gutiérrez F, Cantero-Fortiz Y, Alegret M, Pytel V, Cañabate P, et al. Exploring sex differences in Alzheimer’s disease: A comprehensive analysis of a large patient cohort from a memory unit. Alzheimers Res Ther. 2025;17(1):27. doi: 10.1186/s13195-024-01656-9.
  2. Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2019. Front Aging Neurosci. 2022;14:937486. doi: 10.3389/fnagi.2022.937486.
  3. Khartabil N, Awaness A. Targeting amyloid pathology in early Alzheimer’s: The promise of Donanemab-Azbt. Pharmacy. 2025;13(1):23. doi: 10.3390/pharmacy13010023.
  4. Peng L, Zhang Z, Li Q, Song Z, Yan C, Ling H. Unveiling the multifaceted pathogenesis and therapeutic drugs of Alzheimer’s disease: A comprehensive review. Heliyon. 2024;10(20):e39217. doi: 10.1016/j.heliyon.2024.e39217.
  5. Ricciarelli R, Fedele E. The amyloid cascade hypothesis in Alzheimer’s disease: It’s time to change our mind. Curr Neuropharmacol. 2017;15(6):926–935. doi: 10.2174/1570159X15666170116143743.
  6. Yadollahikhales G, Rojas JC. Anti-amyloid immunotherapies for Alzheimer’s disease: A 2023 clinical update. Neurotherapeutics. 2023;20(4):914–931. doi: 10.1007/s13311-023-01405-0.
  7. Johnson RA, Rid A, Emanuel E, Wendler D. Risks of phase I research with healthy participants: A systematic review. Clin Trials. 2016;13(2):149–160. doi: 10.1177/1740774515602868.
  8. Salloway S, Lee E, Papka M, Pain A, Oru E, Ferguson MB, et al. TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease. BJPsych Open. 2023;9(S1):S67. doi: 10.1192/bjo.2023.227.
  9. Khartabil N, Awaness A. Targeting amyloid pathology in early Alzheimer’s: The promise of Donanemab-Azbt. Pharmacy. 2025;13(1):23.
  10. Shcherbinin S, Andersen SW, Evans CD, Lo AC, Lu M, Navitsky M, et al. TRAILBLAZER‐ALZ study: Dynamics of amyloid reduction after donanemab treatment. Alzheimers Dement. 2021;17:e057492.
  11. Osaka H, Nishida K, Kanazawa T. Beyond lecanemab: Examining Phase III potential in Alzheimer’s therapeutics. PCN Rep. 2024;3(1):e185. doi: 10.1002/pcn5.185.
  12. Ameen TB, Kashif SN, Abbas SM, Babar K, Ali SM, Raheem A. Unraveling Alzheimer’s: The promise of aducanumab, lecanemab, and donanemab. Egypt J Neurol Psychiatry Neurosurg. 2024;60(1):72. doi: 10.1186/s41983-024-00845-5.
  13. Rabinovici GD, Selkoe DJ, Schindler SE, Aisen P, Apostolova LG, Atri A, et al. Donanemab: Appropriate use recommendations. J Prev Alzheimers Dis. 2025;12(5):100150. doi: 10.1016/j.tjpad.2025.100150.
  14. Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Grassi CM, et al. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis. 2022;9(2):211–220. doi: 10.14283/jpad.2022.21.
  15. Atri A, Llibre‐Guerra JJ, Clifford DB, McDade E, Li Y, Mills S, et al. Insights into high‐risk or unusual ARIA: Manifestations and individualized approaches to management through cases from DIAN‐TU gantenerumab open‐label study. Alzheimers Dement. 2025;20(Suppl 8):e094833. doi: 10.1002/alz.094833.
  16. Jones KE, Aakre JA, Castillo AM, Ramanan VK, Kremers WK, Jack CR Jr, et al. Eligibility for donanemab trial in a population-based study of cognitive aging. J Prev Alzheimers Dis. 2025;12(4):100088. doi: 10.1016/j.tjpad.2025.100088.
  17. Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US. JAMA Neurol. 2022;79(5):478–487. doi: 10.1001/jamaneurol.2022.0315.
  18. Wahid A, Fatima Khan W, Khan Y. Promising advances in Alzheimer’s treatment: Donanemab’s impact on disease progression and amyloid clearance. Ther Adv Neurol Disord. 2024;17:17562864241228650. doi: 10.1177/17562864241228650.
  19. Daly T, Kepp KP, Imbimbo BP. Are lecanemab and donanemab disease‐modifying therapies? Alzheimers Dement. 2024;20(9):6659–6661. doi: 10.1002/alz.14114.
Regular Issue Subscription Original Research
Volume 15
Issue 03
Received 18/08/2025
Accepted 01/12/2025
Published 09/12/2025
Publication Time 113 Days
80

Login


My IP

PlumX Metrics